-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-120
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-120 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-320 in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-320 in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-320 in Atherosclerosis Drug Details: CTX-320 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-310 in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-310 in Hypertriglyceridemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-310 in Hypertriglyceridemia Drug Details: CTX-310 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CTX-131 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-131 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-131 in Cervical Cancer Drug Details: CTX-131 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CTX-131 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-131 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-131 in Endometrial Cancer Drug Details: CTX-131 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-310 in Mixed Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-310 in Mixed Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-310 in Mixed Dyslipidemia Drug Details: CTX-310 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CTX-120 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-120 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-120 in Relapsed Multiple Myeloma Drug Details: CTX-120 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CTX-120 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-120 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-120 in Refractory Multiple Myeloma Drug Details: CTX-120 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CTX-131 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-131 in Malignant Pleural Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-131 in Malignant Pleural Mesothelioma Drug Details: CTX-131 is under development...